151 related articles for article (PubMed ID: 28540759)
1. Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy.
Lee SE; Choi SY; Kim SH; Song HY; Yoo HL; Lee MY; Hwang HJ; Kang KH; Kee KM; Jang EJ; Kim DW
Leuk Lymphoma; 2018 Jan; 59(1):105-113. PubMed ID: 28540759
[TBL] [Abstract][Full Text] [Related]
2. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
[TBL] [Abstract][Full Text] [Related]
3. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
Murai K; Akagi T; Shimosegawa K; Sugawara T; Ishizawa K; Ito S; Murai K; Motegi M; Yokoyama H; Noji H; Tajima K; Kimura J; Chou T; Ogawa K; Harigae H; Kubo K; Oba K; Sakamoto J; Ishida Y
Eur J Haematol; 2015 Dec; 95(6):558-65. PubMed ID: 25703064
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia.
Vasconcelos AP; Azevedo IF; Melo FCBC; Neves WB; Azevedo ACAC; Melo RAM
Genet Mol Res; 2017 Apr; 16(2):. PubMed ID: 28437552
[TBL] [Abstract][Full Text] [Related]
5. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
6. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
Rostami G; Hamid M; Jalaeikhoo H
Gene; 2017 Sep; 627():202-206. PubMed ID: 28627443
[TBL] [Abstract][Full Text] [Related]
7. Fluorescent In Situ Hybridization Monitoring and Effect of Detected Early Responses in the Outcome of Patients With Chronic Phase Chronic Myeloid Leukemia: A Report From a Latin American Country.
Bourlon C; Hernandez-Mata C; Vargas-Serafín C; Bourlon MT; Tuna-Aguilar E; Aguayo A
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):453-9. PubMed ID: 27259590
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Hochhaus A; Müller MC; Radich J; Branford S; Kantarjian HM; Hanfstein B; Rousselot P; Kim DW; Lipton JH; Bleickardt E; Lambert A; Hughes TP
Leukemia; 2009 Sep; 23(9):1628-33. PubMed ID: 19641527
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir.
Azad NA; Shah ZA; Pandith AA; Khan MS; Rasool R; Rasool J; Aziz SA
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1479-1485. PubMed ID: 29936718
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
11. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.
Quintás-Cardama A; Kantarjian H; Jones D; Shan J; Borthakur G; Thomas D; Kornblau S; O'Brien S; Cortes J
Blood; 2009 Jun; 113(25):6315-21. PubMed ID: 19369233
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
[TBL] [Abstract][Full Text] [Related]
13. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Marin D; Ibrahim AR; Lucas C; Gerrard G; Wang L; Szydlo RM; Clark RE; Apperley JF; Milojkovic D; Bua M; Pavlu J; Paliompeis C; Reid A; Rezvani K; Goldman JM; Foroni L
J Clin Oncol; 2012 Jan; 30(3):232-8. PubMed ID: 22067393
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
15. Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.
Pagnano KBB; Miranda EC; Delamain MT; Duarte GO; de Paula EV; Lorand-Metze I; de Souza CA
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):728-733. PubMed ID: 28822797
[TBL] [Abstract][Full Text] [Related]
16. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
Hanfstein B; Lauseker M; Hehlmann R; Saussele S; Erben P; Dietz C; Fabarius A; Proetel U; Schnittger S; Haferlach C; Krause SW; Schubert J; Einsele H; Hänel M; Dengler J; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Pfirrmann M; Hasford J; Hofmann WK; Hochhaus A; Müller MC;
Haematologica; 2014 Sep; 99(9):1441-7. PubMed ID: 24837466
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.
Hughes TP; Saglio G; Quintás-Cardama A; Mauro MJ; Kim DW; Lipton JH; Bradley-Garelik MB; Ukropec J; Hochhaus A
Leukemia; 2015 Sep; 29(9):1832-8. PubMed ID: 26118315
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
Brümmendorf TH; Cortes JE; Khoury HJ; Kantarjian HM; Kim DW; Schafhausen P; Conlan MG; Shapiro M; Turnbull K; Leip E; Gambacorti-Passerini C; Lipton JH
Br J Haematol; 2016 Jan; 172(1):97-110. PubMed ID: 26537529
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia.
Kee KM; Kim SH; Yang SY; Shin JU; Nam YW; Jang EJ; Kim HT; Lee SM; Park SH; Kim DW
Leuk Res; 2022 Jan; 112():106754. PubMed ID: 34906861
[TBL] [Abstract][Full Text] [Related]
20. Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.
Kwak JY; Kim SH; Oh SJ; Zang DY; Kim H; Kim JA; Do YR; Kim HJ; Park JS; Choi CW; Lee WS; Mun YC; Kong JH; Chung JS; Shin HJ; Kim DY; Park J; Jung CW; Bunworasate U; Comia NS; Jootar S; Reksodiputro AH; Caguioa PB; Lee SE; Kim DW
Clin Cancer Res; 2017 Dec; 23(23):7180-7188. PubMed ID: 28939746
[No Abstract] [Full Text] [Related]
[Next] [New Search]
